{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:01:53Z","timestamp":1765609313642},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,3,15]],"date-time":"2006-03-15T00:00:00Z","timestamp":1142380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s10549-005-9136-1","type":"journal-article","created":{"date-parts":[[2006,3,14]],"date-time":"2006-03-14T17:00:27Z","timestamp":1142355627000},"page":"99-108","source":"Crossref","is-referenced-by-count":5,"title":["Pathology of borderline HER-2\/neu breast carcinoma: a biologically distinct phenotype"],"prefix":"10.1007","volume":"98","author":[{"given":"Jeffrey L.","family":"Killeen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ortega-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Shaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven H.","family":"Shaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,3,15]]},"reference":[{"key":"9136_CR1","unstructured":"Cancer Facts & Figures. American Cancer Society, www.cancer.org, 2005"},{"key":"9136_CR2","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","volume":"18","author":"G Pauletti","year":"2000","unstructured":"Pauletti G, Dandekar S, Rong HM, Ramos L, Peng H, Seshadri R, Slamon DJ, Assessment of methods for tissue-based detection of the HER-2\/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry J Clin Oncol 18: 3651\u20133664, 2000","journal-title":"J\u2423Clin Oncol"},{"key":"9136_CR3","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1001\/jama.291.16.1972","volume":"291","author":"H Yaziji","year":"2004","unstructured":"Yaziji H, Goldstein L, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AG, HER-2 testing in breast cancer using parallel tissue-based methods JAMA 291: 1972\u20131977, 2004","journal-title":"JAMA"},{"key":"9136_CR4","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1309\/Y73U8X72B68TMGH5","volume":"121","author":"K Bloom","year":"2004","unstructured":"Bloom K, Harrington D, Enhanced accuracy and reliability of HER-2\/neu immunohistochemical scoring using digital microscopy Am J Clin Pathol 121: 620\u2013630, 2004","journal-title":"Am J Clin Pathol"},{"key":"9136_CR5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1309\/TMUW-G4WB-LXJ2-FUDN","volume":"116","author":"S Wang","year":"2001","unstructured":"Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Wians FH, Hynan L, Ashfaq R, Assessment of HER-2\/neu status in breast cancer: automated cellular imaging system (ACIS) \u2013 assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard Am J Clin Pathol 116: 495\u2013503, 2001","journal-title":"Am J Clin Pathol"},{"key":"9136_CR6","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/jnci\/dji249","volume":"97","author":"G Arpino","year":"2005","unstructured":"Arpino G, Weiss H, Lee AV, Schiff R, De Pacido S, Osborne CK, Elledge RM, Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistence J Natl Cancer Inst 97: 1254\u20131261, 2005","journal-title":"J Natl Cancer Inst"},{"key":"9136_CR7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO, Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology19: 403\u2013410, 1991","journal-title":"Histopathology"},{"key":"9136_CR8","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1200\/JCO.2001.19.10.2714","volume":"19","author":"RR Tubbs","year":"2001","unstructured":"Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkin RB, Grogan TM, Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message J Clin Oncol 19: 2714\u20132721, 2001","journal-title":"J Clin Oncol"},{"key":"9136_CR9","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","volume":"20","author":"MF Press","year":"2002","unstructured":"Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L, Evaluation of HER-2\/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol 20: 3095\u20133105, 2002","journal-title":"J Clin Oncol"},{"key":"9136_CR10","unstructured":"Killeen JL, Fu JB: Validation of HER-2\/neu testing by image analysis. Breast Cancer Research and Treatment 88, supplement 1, San Antonio Breast Cancer Symposium, 2004, p. S45\u2013S46"},{"key":"9136_CR11","unstructured":"Perez E: Update of Breast Intergroup Trial N9831. Proc American Society of Clinical Oncology, 2004, p. 19s"},{"key":"9136_CR12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.humpath.2004.11.010","volume":"36","author":"DG Hicks","year":"2005","unstructured":"Hicks DG, Tubbs RR, Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines Human Pathol 36: 250\u2013261, 2005","journal-title":"Human Pathol"},{"key":"9136_CR13","doi-asserted-by":"crossref","unstructured":"Zarbo RJ, Hammond EH: Her-2\/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 127. Conference Summary, Strategic Science Symposium, 2003, pp. 549\u2013553","DOI":"10.5858\/2003-127-0549-CSSSS"},{"key":"9136_CR14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1309\/YMJ3A83TB39MRUT9","volume":"123","author":"P Lal","year":"2005","unstructured":"Lal P, Tan LK, Chen B, Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3655 invasive breast carcinomas Am J Clin Pathol 123: 541\u2013546, 2005","journal-title":"Am J Clin Pathol"},{"key":"9136_CR15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1053\/S0046-8177(03)00409-X","volume":"34","author":"L Hammock","year":"2003","unstructured":"Hammock L, Lewis M, Phillips C, Cohen C, Strong HER-2\/neu Protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization Hum Pathol 34: 1043\u20131047, 2003","journal-title":"Hum Pathol"},{"key":"9136_CR16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00066982-200005030-00006","volume":"5","author":"S Kakar","year":"2000","unstructured":"Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML, HER-2\/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival Mol Diagn 5: 199\u2013207, 2000","journal-title":"Mol Diagn"},{"key":"9136_CR17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1075-122x.2005.21463.x","volume":"11","author":"R Ariga","year":"2005","unstructured":"Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P, Correlation of Her-2\/neu gene amplification with other prognostic and predictive factors in female breast carcinoma Breast J 11: 278\u2013280, 2005","journal-title":"Breast J"},{"key":"9136_CR18","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1023\/A:1008313310474","volume":"11","author":"O Stal","year":"2000","unstructured":"Stal O, Borg A, Ferno M, Kallstrom AC, Malmstrom P, Nordenskjold B, ErbB2 status and the benefit from two to five years of adjuvant tamoxifen in postmenopausal early stage breast cancer Ann Oncol 11: 1545\u20131550, 2000","journal-title":"Ann Oncol"},{"key":"9136_CR19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0304-3835(94)90194-5","volume":"81","author":"A Borg","year":"1994","unstructured":"Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, Sigurdsson H, ERBB2 amplification is associated with tamoxifen resistance in steroid receptor positive breast cancer Cancer Lett 81: 137\u2013144, 1994","journal-title":"Cancer Lett"},{"key":"9136_CR20","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/sj.bjc.6690196","volume":"79","author":"SJ Houston","year":"1999","unstructured":"Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW, Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer Br J Cancer 79: 1220\u20131226, 1999","journal-title":"Br J Cancer"},{"key":"9136_CR21","first-page":"70a","volume":"18","author":"B Nordenskjold","year":"1999","unstructured":"Nordenskjold B, Hatschek T, Kallstrom A, Results of prolonged adjuvant tamoxifen therapy in breast cancer correlated to steroid receptor, S-phase and erbB2 levels Proc Am Soc Clin Oncol , 1999, 18:70a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"9136_CR22","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/djg068","volume":"95","author":"F Spyratos","year":"2003","unstructured":"Spyratos F, Bouchet C, Ferrero-Po\u00fcs M, Tubiana-Hulin M, Hacene K, Quantitative association between HER-2\/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer J Natl Cancer Inst 95: 1417, 2003","journal-title":"J Natl Cancer Inst"},{"key":"9136_CR23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet351: 1451\u20131467, 1998","journal-title":"Lancet"},{"key":"9136_CR24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/172460089901400202","volume":"14","author":"D Coradini","year":"1999","unstructured":"Coradini D, Oriana S, Biganzoli E, Marubini E, Boracchi P, Bresciani G, Di Fronzo G, Daidone MG, Relationship between steroid receptors (as continuous variables) and response to adjuvant treatments in postmenopausal women with node-positive breast cancer Int J Biol Markers 14: 60\u201367, 1999","journal-title":"Int J Biol Markers"},{"key":"9136_CR25","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","volume":"17","author":"JM Harvey","year":"1999","unstructured":"Harvey JM, Clark GM, Osborne CK, Allred DC, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17: 1474\u20131481, 1999","journal-title":"J Clin Oncol"},{"key":"9136_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W","volume":"89","author":"RM Elledge","year":"2000","unstructured":"Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK, Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study Int J Cancer 89: 111\u2013117, 2000","journal-title":"Int J Cancer"},{"key":"9136_CR27","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2003.09.099","volume":"21","author":"VJ Bardou","year":"2003","unstructured":"Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM, Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases J Clin Oncol 21: 1973\u20131979, 2003","journal-title":"J Clin Oncol"},{"key":"9136_CR28","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1200\/JCO.1992.10.8.1284","volume":"10","author":"PM Ravdin","year":"1992","unstructured":"Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study J Clin Oncol 10: 1284\u20131291, 1992","journal-title":"J Clin Oncol"},{"key":"9136_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/172460089901400104","volume":"14","author":"E Tagliabue","year":"1999","unstructured":"Tagliabue E, Menard S, Robertson JF, Harris L, C-erbB-2 expression in primary breast cancer Int J Biol Markers 14: 16\u201326, 1999","journal-title":"Int J Biol Markers"},{"key":"9136_CR30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","volume":"95","author":"G Konecny","year":"2003","unstructured":"Konecny G, Pauletti G, Pegram M, Untch M, Dandkar S, Aguilar Z, Wilson C, Rong H-M, Bauerfeind I, Felber M, Wang H-J, Beryt M, Seshadri R, Hepp H, Slamon DJ, Quantitative association between HER-2\/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer J Natl Cancer Inst 95: 142\u2013153, 2003","journal-title":"J Natl Cancer Inst"},{"key":"9136_CR31","first-page":"105","volume":"51","author":"SA Fuqua","year":"1991","unstructured":"Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O\u2019Malley BW, McGuire WL, Variant human breast tumor estrogen receptor with constitutive transcriptional activity Cancer Res 51: 105\u2013109, 1991","journal-title":"Cancer Res"},{"key":"9136_CR32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0303-7207(99)00125-2","volume":"156","author":"H Wang","year":"1999","unstructured":"Wang H, Zeng X, Khan SA, Estrogen receptor variants Erdelta5 and Erdelta7 down-regulate wild-type estrogen activity Mol Cell Endocrinol 156: 159\u2013168, 1999","journal-title":"Mol Cell Endocrinol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-005-9136-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-005-9136-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-005-9136-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T21:14:33Z","timestamp":1627161273000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-005-9136-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,15]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["9136"],"URL":"https:\/\/doi.org\/10.1007\/s10549-005-9136-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,15]]}}}